BioUtah retweeted
“Halia is working to crack inflammatory disorders.”
Thanks to @KennedyForUtah for spotlighting us during the Science, Space & Tech Committee hearing, and to @BioUtah for your advocacy!
#HaliaTx #UtahBiotech #SciencePolicy #GeneticResilience
BioUtah retweeted
Utah showed up strong at #BIO2025 💥
Proud to join @BioUtah and partners from across the state to spotlight Utah’s booming life sciences sector. From infrastructure to incentives, UIPA is helping build what’s next.
📍#BIO2025 | Boston
#LifeSciences #UIPA #UtahInnovation
BioUtah retweeted
Renew Biotechnologies CEO Chad Pollard
00:00 - Introduction and guest welcome
00:19 - From med school to biotech: The origin story
00:51 - Early research and the birth of Renew Biotechnologies
01:33 - Discussing Neuralink and the potential to cure ALS
02:33 - How early detection can lead to cures
02:44 - Introduction to Renew Biotechnologies and their focus
03:54 - Success stories and the impact of their technology
06:59 - The timeline and process for bringing a biotech product to market
09:07 - The role of AI in diagnostics and healthcare
10:28 - Long-term impact of AI in healthcare
12:07 - Changes in administration and their impact on biotech
14:21 - A day in the life of a biotech CEO
15:57 - Company growth and future plans
17:21 - Building a biotech company in Utah
19:34 - Utah's biotech community and its growth
21:53 - The role of universities in biotech innovation
24:04 - Venture capital and funding challenges in biotech
25:44 - Reading recommendations for CEOs
26:30 - Balancing work with personal interests
28:39 - Future vision for Renew Biotechnologies
29:33 - Unique company structure and incentivizing innovation
31:40 - The importance of integrity in healthcare
33:10 - Acknowledging those who gave a chance
BioUtah retweeted
Excerpt: Navigating Federal Regulations: The Pill Penalty
The pharmaceutical landscape is changing rapidly, particularly due to federal regulations that can significantly impact drug development. One such regulation is the so-called “pill penalty” introduced under the Inflation Reduction Act. This provision mandates that certain companies must negotiate drug prices with Medicare, but the process is far from straightforward.
This negotiation is not a true negotiation; failing to comply results in a staggering 95% excise tax on their products. In essence, this creates a situation where companies feel coerced into accepting prices dictated by the government. The intention behind this measure was to reduce healthcare costs, but it has raised serious concerns about its real benefits for patients.
Moreover, the regulations favor large molecule drugs over small molecule drugs, which raises questions about equity in drug development. Large molecule drugs are given a 13-year window before price negotiations kick in, while small molecule drugs only receive a mere 9 years. This discrepancy discourages investment in small molecule drugs, ultimately limiting the options available to patients.
BioUtah retweeted
Navigating the Future of Life Sciences in Utah: Insights from Kelvyn Cullimore politicit.com/navigating-the…
BioUtah retweeted
🧬 As a @RareDiseases corporate council member & sponsor of the @rarediseaseday awareness campaign, we’re committed to spreading awareness around rare diseases – including the patients and their families who are impacted, and the researchers and physicians who are working toward a cure.
▪️ Today at our company All Hands we heard from a rare disease patient who has been able to manage his condition due to diagnosis and treatment and is currently completing his graduate studies at @UUtah as well as from Josh Bonkowsky, MD PhD, Chief, Division of Pediatric Neurology & Director, Primary Children's Center for Personalized Medicine at University of Utah, who is using rapid whole genome sequencing among other methods to help accelerate personalized treatments.
📅 Tomorrow, Feb. 27, 4:30-7pm MT, in celebration of Rare Disease Day, we’re welcoming speakers from across Utah’s rare disease and health innovation community to share their stories. The event is available in person and online and is open to the public.
🔹 Speakers include:
▪️ Dr. Tracy George Unit and Chief Scientific Officer, ARUP Laboratories & Professor of Pathology, Spencer Fox Eccles School of Medicine, University of Utah
▪️ Aimee Edwards, Executive Director, @BioHiveUtah
▪️ Kelvyn Cullimore, President & CEO, @BioUtah
▪️ Sylvia Lam, Advocate, @UtahRDAC
▪️ Ava Szajnuk, Undiagnosed Rare Disease Patient, Rare and Undiagnosed Network (RUN)
▪️ Rachel Palmquist, University of Utah Health, Intermountain Genetic Counselor, Primary Children’s Gene Kids
▪️ Stacey L. Clardy, MD PhD FAAN, MD PhD, Associate Professor of Neurology, University of Utah & Salt Lake City VAMC
Recursion Co-founder and CEO @RecursionChris and Chief R&D Officer and Chief Commercial Officer Najat Khan, PhD will provide closing remarks.
Join us!
✍ Details and registration here: lu.ma/itz526zb
#rarediseaseday
BioUtah retweeted
At the 2025 Life Sciences Day on the Hill. Thanks to @BioUtah for the invite and to the lawmakers and staffers. It was great to show the technology being developed in Utah. fluidxmedical.com/ #oncology #embolization #interventionalradiology #interventionaloncology
BioUtah retweeted
Recursion is celebrating @rarediseaseday on Thurs., Feb. 27, 4:30-7pm MT, bringing together Utah leaders, patients, and patient advocates who are working to find new cures. Join us in person or online as we welcome speakers from across Utah’s rare disease and health innovation community, including:
▪️ Dr. Tracy George, President, Innovation Business Unit and Chief Scientific Officer, ARUP Laboratories & Professor of Pathology, Spencer Fox Eccles School of Medicine, @UUtah
▪️ Aimee Edwards, Executive Director, @BioHiveUtah
▪️ Kelvyn Cullimore, President & CEO, @BioUtah
▪️ Sylvia Lam, Rare Disease Advocate, Utah Rare Disease Advisory Council (RDAC)
▪️ Ava Szajnuk, Undiagnosed Rare Disease Patient, @rareundiagnosed
▪️ Josh Bonkowsky, MD PhD, Chief, Division of Pediatric Neurology & Director, Primary Children's Center for Personalized Medicine
▪️ Rachael Palmquest, University of Utah Health, Intermountain Genetic Counselor, Primary Children’s Gene Kids
▪️ Stacey L. Clardy, MD PhD FAAN, MD PhD, Associate Professor of Neurology, University of Utah & Salt Lake City VAMC
Recursion Co-founder and CEO @RecursionChris and Chief R&D Officer and Chief Commercial Officer Najat Khan, PhD will provide closing remarks.
👉 Details and registration here: lu.ma/itz526zb #rarediseaseday
BioUtah retweeted
Randall Taylor, @PresidentUofU (far right), explained at today’s @BioUtah #LifeSciencesSummit that his goal is to transform the @UUtah into collaborative, fast-moving partner to existing & prospective #LifeScience #entrepreneurs in #Utah.
BioUtah retweeted
Last week, the Seek Labs team had the honor of attending the 2024 Utah Life Sciences Summit. Congratulations to the @BioUtah team for organizing such an exceptional summit that united innovators and leaders across Utah’s life sciences ecosystem.
Recently, GOEO's Utah Innovation Center sponsored @BioUtah's Life Sciences Summit 2024 — Utah's premier gathering for the life sciences community. Innovators, researchers, and leaders came together to learn, foster connections, and celebrate Utah's life sciences ecosystem.
BioUtah retweeted
We are proud to sponsor @BioUtah's Utah Life Sciences Summit! Register and connect with industry leaders and gain insights on trends shaping the future of life sciences: wsgr.com/en/events/2024-utah…
Also, check out this short video on life sciences in Utah: vimeo.com/1026723909
THANK YOU to our contributing sponsors! Your support makes #UtahLifeSciencesSummit the premier event it is. Join us tomorrow: utahlifesciencessummit.com/
#2024ULSS
@PhRMA
@DiscGenics
@Kimbell_Assoc
Utah Governor's Office of Economic Opportunity
Influence Relocation
Squire
I will give a talk at @BioUtah 2024 Utah #LifeSciences Summit on Equity and Non-diutive Funding for #WomensHealth Companies. Hoping for a great turnout! #ULSS2024 - via #Whova event app
BioUtah retweeted
SCI affiliate faculty member @WarrenWPettine is moderating this AI in life sciences panel at 2 pm this Thurs, 11/14. The Utah Life Sciences Summit features speakers from academia (including other U faculty & leaders), government, & industry—details at utahlifesciencessummit.com.
Within life sciences, AI is already having a profound & rapidly evolving impact. Join us at the #2024ULSS for a special panel to discuss all things AI within the life sciences sector. Register: utahlifesciencessummit.com/
#BioUtah #UtahLifeSciences #2024ULSS #UtahLifeSciencesSummit
BioUtah retweeted
The @US_FDA has published a digital health and artificial intelligence glossary to serve as an educational resource to help support consistent use of digital health and AI terminology by the FDA and interested parties. fda.gov/science-research/art…
BioUtah retweeted
Announcing the launch of Siege™ Vascular Plug, the latest in our comprehensive Embolics portfolio. Explore how we understand, innovate, and deliver for our healthcare partners and patients: bit.ly/4gCUPBG
For safety info and IFU: bit.ly/4gCUPBG
The latest in @uutah startup news:
-@3Helix_Inc places 2nd in Startup State Entrepreneur Challenge
-@RecursionPharma appoints Najat Khan as Chief R&D Officer and Chief Commercial Officer
technologylicensing.utah.edu…
BioUtah retweeted
Halia Therapeutics and Biolexis Therapeutics have teamed up to develop a new drug targeting NLRP3-driven neuroinflammation!
Read the press release for more details: loom.ly/5nOurFs
#Parkinsons #neurodegeneration #drugdevelopment #HaliaTx #Biolexistx
BioUtah retweeted
Republicans and Democrats agree: #PBMs are the barriers to accessible, affordable, and quality health care.
🎉 AAPS is excited to announce the plenary speakers for #PharmSci360.
➡️ Join us on October 20 for a #panel discussion on #research integrity.
➡️Piet van der Graaf, Ph.D., @Certara, closes out PharmSci 360 on October 23 with a talk on #AI.
Register: bit.ly/PharmSci3602024Plenar…

































